Levosimendan Intermediate CAS 36725-28-7 Kemurnian >99,5% (HPLC) Pabrik
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 6-(4-Aminophenyl)-4,5-Dihydro-5-Methyl-3(2H)-Pyridazinone (CAS: 36725-28-7) with high quality, commercial production. We can provide COA, worldwide delivery, small and bulk quantities available. Please contact: alvin@ruifuchem.com
Jeneng Kimia | 6-(4-Aminophenyl)-4,5-Dihydro-5-Methyl-3(2H)-Pyridazinone |
sinonim | 6-(p-Aminophenyl)-5-methyl-4,5-dihydro-3(2H)-pyridazinone;1,4-Dihydro-4-Methyl-3-(4-Aminophenyl)pyridazine-6(5H)-siji;Pengotor Levosimendan 5 |
Nomer CAS | 36725-28-7 |
Nomer CAT | RF-PI1976 |
Status Simpenan | Ing Simpenan, Skala Produksi Nganti Ton |
Formula Molekul | C11H13N3O |
Bobot Molekul | 203.25 |
Titik Lebur | 194,0 kanggo 198,0 ℃ |
Kapadhetan | 1,30±0,10 g/cm3 |
Merk | Kimia Ruifu |
Item | Spesifikasi |
Penampilan | Werna Werna Werna Putih Putih nganti Coklat Pucat |
Identifikasi (HPLC) | HPLC RT saka puncak utama cocog karo standar kerja ing omah |
Mundhut ing Pangatusan | <0,50% |
Sisa ing Ignition | <0,20% |
Zat sing gegandhengan | (HPLC) |
Impurity Tunggal | <0,20% |
Total Impurities | <0,50% |
Kemurnian / Metode Analisis | > 99,5% (HPLC) |
Logam abot | <20 ppm |
Proton NMR Spectrum | Conforms kanggo Struktur |
Test Standar | Standar Perusahaan |
Panggunaan | Penengah Levosimendan (CAS: 141505-33-1) |
Paket: Botol, tas Aluminium foil, 25kg / Karton Drum, utawa miturut kabutuhan pelanggan
Kondisi panyimpenan:Simpen ing wadhah sing disegel ing papan sing adhem lan garing;Nglindhungi saka cahya lan Kelembapan
6-(4-Aminophenyl)-4,5-Dihydro-5-Methyl-3(2H)-Pyridazinone (CAS: 36725-28-7) minangka perantara Levosimendan (CAS: 141505-33-1).Levosimendan dikenalake ing Swedia minangka infus iv kanggo perawatan gagal jantung akut utawa gejala refraktori gagal jantung kronis ing kasus nalika perawatan konvensional (contone, diuretik utawa inhibitor ACE) ora cukup.Uga ngaktifake saluran kalium sing diatur adenostne trifosfat ventrikel lan arteri sing nyebabake vasodilatasi ing otot polos pembuluh darah lan nglindhungi miokardium saka infark.Aktivitas nyandhet fosfodiesterase III sing kurang mbokmenawa ora tanggung jawab kanggo efek inotropik, lusitropik lan dilating sing positif.Ora kaya obat kardiotonik liyane, levosimendan bisa ngasilake efek inotropik sing positif tanpa nambah relaksasi miokard utawa nambah insiden aritmia ganas.Sacara klinis ditampilake duwe risiko kematian sing luwih murah ing pasien gagal jantung yen dibandhingake karo plasebo lan dobutamine.Amarga nduweni potensi sing luwih gedhe, levosimendan saiki ana ing evaluasi klinis luwih lanjut minangka perawatan kronis kanggo gagal jantung kongestif.